HAL and MIDHANI in focus: HAL places Rs 6,000 crore superalloy order with MIDHANI, says report
Superalloys — which deliver exceptional strength, heat resistance, and durability — are indispensable for high-performance engines and machinery. With global supply chains facing uncertainty, HAL has tapped MIDHANI as a reliable domestic supplier for these advanced materials. The move also mitigates the risks associated with dependence on imported components.
MIDHANI is set to supply a wide range of nickel-based superalloys enriched with chromium, aluminum, titanium, as well as cobalt-based and titanium-based alloys. These materials will not only power AL31 engines but also support indigenous engines and future programs like the GE F414 for Tejas Mk2 and the AMCA engine.
According to Alpha Defense, this initiative represents a strategic shift toward indigenization of jet engines and tighter control over critical supply chains. The deal will help India replace imported parts, strengthen its industrial base, and reduce vulnerabilities in a region marked by geopolitical tensions.
MIDHANI, often referred to as India's superalloy powerhouse, continues to lead in supplying premium alloys for extreme environments like jet turbines, power plants, and critical infrastructure sectors.
The order is expected to pave the way for India's next-generation engine programs, bolstering domestic capabilities and supporting HAL's upcoming strategic programs with confidence.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
7 hours ago
- Business Insider
AMD CEO Lisa Su Says ‘We Absolutely Should Bring Manufacturing Back to the US'
Advanced Micro Devices (AMD) CEO Lisa Su was asked about incentives to bring chip manufacturing to the U.S. during an interview with Wired. In response, she said, 'We absolutely should bring manufacturing back to the US. Absolutely, 100 percent.' Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. When asked why Su believes manufacturers should return to the U.S., she highlighted several advantages to doing so. Included among them were national security, economic interests, and good business practice. All of this is part of an effort to diversify supply chains and avoid delays, such as those caused during the lockdowns of the COVID-19 pandemic. While some have been skeptical about returning chip fabrication to the U.S., Su believes it is doable. However, it will come at a cost. The AMD CEO noted, 'It is more expensive, and that's OK, too. I think it requires a change of mentality, that you don't always go for the lowest-cost thing.' AMD Stock Movement Today AMD stock was up 0.07% on Tuesday, extending a 42.7% year-to-date rally. The shares have also increased 22.07% over the past 12 months. A recent catalyst for AMD shares was a deal with the U.S. government to sell AI chips in China. This will have it pay 15% of these sales to the government. Rival semiconductor company Nvidia (NVDA) has signed the same deal to allow AI chip sales to China. While this could impact the two companies' financials, it opens the way for chip sales to an area with high demand. Is AMD Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for AMD is Moderate Buy, based on 26 Buy and 12 Hold ratings over the past three months. With that comes an average AMD stock price target of $181.36, representing a potential 5.46% upside for the shares.
Business Upturn
10 hours ago
- Business Upturn
Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market
Mumbai-based Indoco Remedies Ltd. has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market Rivaroxaban Tablets USP in strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg. The product is the generic equivalent of Janssen Pharmaceuticals' blockbuster anticoagulant, Xarelto, and will be manufactured at Indoco's Verna, Goa facility. The approved Rivaroxaban tablets are bioequivalent and therapeutically equivalent to Xarelto and are indicated for the treatment of venous thromboembolism (VTE). This approval marks another milestone in Indoco's push into the US generics market, one of the most lucrative pharmaceutical markets globally. Commenting on the development, Indoco Remedies' Managing Director Aditi Panandikar said, 'Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.' Indoco Remedies is a fully integrated, research-driven pharmaceutical company with a global footprint, generating over 106 million prescriptions annually in India alone. The company operates 11 manufacturing facilities — seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs) — all of which are approved by top global regulatory agencies including the USFDA and UK-MHRA. With a turnover of $180 million and a workforce of more than 6,000 employees, Indoco is known for popular domestic brands such as Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, and Cital. Internationally, the company partners with large generics players to expand its market reach across multiple geographies. The latest USFDA approval strengthens Indoco's product portfolio in the regulated market and could open up significant revenue opportunities as Rivaroxaban continues to be a widely prescribed oral anticoagulant in the US. Disclaimer: This news article is for informational purposes only and does not constitute investment advice. Investors should consult a qualified financial advisor before making investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
10 hours ago
- Business Upturn
Why are Indoco Remedies shares up 2% today? Explained
By Aditya Bhagchandani Published on August 13, 2025, 10:05 IST Indoco Remedies Ltd shares climbed over 2% to ₹299.30 in morning trade on Tuesday after the company announced it has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Rivaroxaban tablets, a generic version of Bayer's blockbuster anticoagulant Xarelto. The approval covers multiple dosage strengths — 2.5 mg, 10 mg, 15 mg, and 20 mg — positioning Indoco to tap into the lucrative US market for blood thinners, which has significant demand due to rising cardiovascular cases. Industry data shows Rivaroxaban sales in the US crossed $2 billion in recent years. Indoco said the launch will be executed through its marketing partner in the US, adding that this development strengthens its complex generics portfolio and enhances its revenue visibility in the American market. The stock's rally reflects investor optimism about the earnings potential from this launch, given that US generics typically offer higher margins than domestic formulations. Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investing in equities involves risks. Please consult a certified financial advisor before making any investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
